Condoluci, A., Romano, I., Dietrich, D., Pini, K., Stussi, G., Müller, G., Cantoni, N., Cathomas, R., Mey, U., Widmer, A., Zenz, T., Gregor, M., Heim, D., Andres, M., Benz, R., Rossi, D. (2025). Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial. Blood. https://doi.org/10.1182/blood.2024026879